Watson stock up on recertification

From Times Wire Services

Shares of Watson Pharmaceuticals Inc., the second-largest U.S. maker of generic drugs, gained the most in almost a year after the Corona-based company’s Florida plant was cleared to make new products for the first time since 2005.

The recertification by the Food and Drug Administration removes hurdles for long-delayed products including copies of AstraZeneca’s antacid Prilosec and blood-pressure medicine Toprol XL.

Watson shares rose $2, or 6.9%, to $31.14.